Lymphoma, T Cell, Cutaneous Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
F
AEDV Registry of Primary Cutaneous Lymphoma
Recruiting
  • Lymphoma, T-Cell, Cutaneous
  • +5 more
  • Registry of patients (exposure is Cutaneous Lymphoma)
  • Barcelona, Spain
  • +13 more
2022-03-15
Mar 15, 2022
T
A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin
Recruiting
  • Hodgkin Disease
  • Lymphoma, T-Cell, Cutaneous
  • No Intervention
  • San Bartolome, Alicante, Spain
  • +29 more
2022-03-10
Mar 10, 2022
4
Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)
Recruiting
  • Mycosis Fungoides
  • +2 more
  • Graz, Austria
  • +67 more
2022-01-27
Jan 27, 2022
E
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL
Recruiting
  • Mycosis Fungoides
  • +2 more
  • Naloxone Hydrochloride Lotion, 0.5%
  • Placebo Lotion
  • Birmingham, Alabama
  • +31 more
2022-01-18
Jan 18, 2022
P
Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas - 2018
Terminated
  • Lymphoma, T-Cell, Cutaneous
  • Mycosis Fungoides
  • Bydgoszcz, Poland
    Centrum Onkologii im. prof. F. Łukaszczyka
2021-12-23
Dec 23, 2021
E
A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)
Recruiting
  • Lymphoma, T-cell, Peripheral
  • Lymphoma, T-cell, Cutaneous
  • Nagoya, Japan
  • +2 more
2021-11-16
Nov 16, 2021
I
Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides
Recruiting
  • Lymphoma, T-Cell, Cutaneous
  • Mycosis Fungoides
  • single-arm, non-randomized Biodynamic imaging (BDI)
  • Indianapolis, Indiana
    Indiana University School of Medicine, Department of Dermatology
2021-11-17
Nov 17, 2021
E
Study of Photopheresis in the Treatment of Erythrodermic MF and SS
Withdrawn
  • Lymphoma, T-Cell, Cutaneous
  • Mycosis Fungoides/Sezary Syndrome
  • Zürich, Switzerland
    UniversitaetsSpital Zurich - Division of Dermatology
2021-08-31
Aug 31, 2021
S
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
Active, not recruiting
  • Mycoses
  • +5 more
  • anti-thymocyte globulin
  • +2 more
  • Stanford, California
    Stanford University School of Medicine
2021-07-29
Jul 29, 2021
I
IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
Recruiting
  • Lymphoma, T-Cell
  • +2 more
  • IPH4102
  • Birmingham, Alabama
  • +42 more
2021-05-28
May 28, 2021
C
Tissue Repository: CTCL Collection Protocol
Recruiting
  • Lymphoma, T-Cell, Cutaneous
  • +2 more
    • New York, New York
      Columbia University Medical Center
    2021-03-10
    Mar 10, 2021
    U
    Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders - 2020
    Terminated
    • Lymphoma, T-Cell, Cutaneous
    • +6 more
    • Ann Arbor, Michigan
      University of Michigan Rogel Cancer Center
    2021-01-20
    Jan 20, 2021
    W
    Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas - 2020
    Completed
    • Lymphoma, T-Cell, Cutaneous
    • +3 more
    • Chicago, Illinois
    • +1 more
    2020-11-16
    Nov 16, 2020
    P
    Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma
    Recruiting
    • Lymphoma, T-Cell, Cutaneous
    • +2 more
    • Lenalidomide 15mg
    • Brentuximab Vedotin 1.8 mg/Kg
    • Melbourne, Victoria, Australia
      Peter MacCallum Cancer Centre
    2020-09-29
    Sep 29, 2020
    S
    A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001
    No longer available
    • Disease, Hodgkin
    • +3 more
    • brentuximab vedotin
    • Stanford, California
    • +30 more
    2020-09-17
    Sep 17, 2020
    E
    PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)
    Active, not recruiting
    • Lymphoma, T-Cell, Cutaneous
    • Mycosis Fungoides/Sezary Syndrome
    • Madrid, Spain
    • +1 more
    2020-07-30
    Jul 30, 2020
    A
    AFM13 in Relapsed/Refractory Cutaneous Lymphomas - 2020
    Completed
    • Lymphoma, T-Cell, Cutaneous
    • New York, New York
      Center for Lymphoid Malignancies
    2020-07-14
    Jul 14, 2020
    R
    Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma - 2018
    Completed
    Has Results
    • Lymphoma, T-Cell, Peripheral
    • Lymphoma, T-Cell, Cutaneous
    • Duarte, California
    • +7 more
    2019-12-23
    Dec 23, 2019
    Y
    Study Of Intratumoral G100 In Cutaneous T Cell Lymphoma
    Withdrawn
    • Lymphoma, T-Cell, Cutaneous
    • Intratumoral G100
    • (no location specified)
    2019-12-16
    Dec 16, 2019
    M
    Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042)
    No longer available
    • Lymphoma, T-Cell, Cutaneous
    • Comparator: vorinostat
    • (no location specified)
    2019-08-13
    Aug 13, 2019
    J
    CTCL Directed Therapy
    Unknown status
    • Lymphoma, T-Cell, Cutaneous
    • Bronx, New York
      James J Peters Bronx Veterans Affairs Medical Center
    2019-08-12
    Aug 12, 2019
    C
    VircapSeq Virus Detection in Sézary Syndrome - 2016
    Completed
    • Lymphoma, T-Cell, Cutaneous
    • Sézary Syndrome
      • New York, New York
        Columbia University Medical Center
      2017-02-06
      Feb 6, 2017
      J
      A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma - 2016
      Completed
      • Lymphoma, T-Cell, Cutaneous
      • Quisinostat, 12 mg
      • Pittsburgh, Pennsylvania
      • +12 more
      2016-11-02
      Nov 2, 2016
      T
      Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL) - 2013
      Completed
      Has Results
      • Lymphoma, T-Cell, Cutaneous
      • placebo for SHAPE (SHP-141)
      • +3 more
      • Stanford, California
      • +5 more
      2016-02-23
      Feb 23, 2016
      S
      A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies - 2003
      Completed
      • Hodgkin Disease
      • +4 more
      • SGN-30 (monoclonal antibody)
      • Birmingham, Alabama
      • +9 more
      2011-10-07
      Oct 7, 2011